The Impact of Recent Personnel Cuts at the U.S. Department of Health and Human Services
Biomedical research is a crucial component in the fight against heart disease, the leading cause of death in the United States. However, it is not the only piece of the puzzle. Public health initiatives play a significant role in supporting the work of scientists and medical professionals. Nutrition education, tobacco regulation, diabetes prevention programs, and other public health efforts complement biomedical research and clinical trials in the battle against heart disease. The recent personnel cuts at the U.S. Department of Health and Human Services (HHS) are set to impact this federally-funded health ecosystem, including public health, biomedical research, clinical trials, and drug approval processes.
The Unfolding Consequences
On March 27, HHS Secretary Robert F. Kennedy, Jr. announced a major restructuring of the Department in line with President Trump’s DOGE Executive Order. This restructuring involves significant reductions in personnel, with layoffs affecting one-quarter of the current HHS workforce. The full extent of the effects of these personnel cuts is yet to be determined. The restructuring may lead to the formation of new consolidated offices, the absorption of work by remaining offices, or the abandonment of certain functions altogether. The reduction in force at HHS is a developing situation with potential implications for science and public health in the United States.
1. Impact on Infectious Disease Prevention and Treatment
The cuts at HHS are already affecting infectious disease prevention and treatment efforts, particularly in areas such as HIV prevention. Offices dedicated to infectious diseases, including the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, have been significantly impacted. The elimination of certain divisions within these offices could disrupt planning and implementation of disease prevention programs, potentially leading to an increase in preventable infections. Furthermore, the termination of grants for infectious disease response and research is compounding the challenges posed by staffing reductions.
Local health departments are also feeling the effects of the personnel cuts, with some being forced to cancel vaccination events for diseases like measles. The reduction in federal support for vaccination efforts and testing and tracking programs could have detrimental consequences for public health outcomes.
2. Challenges in Chronic Disease Research and Prevention
The downsizing of HHS is hindering chronic disease research and prevention efforts. Offices focused on chronic disease prevention and health promotion have been affected by the restructuring, impacting funding for local public health initiatives. Layoffs at NIH institutes studying chronic illnesses like cancer, stroke, diabetes, and aging are also disrupting essential research and clinical trials in these areas.
Smoking research and regulation are also at risk due to the cuts at HHS. Offices dedicated to tobacco research and smoking cessation programs have been significantly impacted, raising concerns about the potential consequences for public health, given smoking’s status as the primary cause of preventable death in the US.
3. Challenges in Environmental Health and Occupational Safety Oversight
The elimination of CDC centers like the National Center for Environmental Health and the National Institute of Occupational Safety and Health is making it harder to monitor and respond to environmental health and occupational safety hazards. Programs aimed at protecting Americans from various health hazards are at risk due to the reduction in force at these centers. This could lead to lapses in monitoring and addressing health risks related to environmental exposures and workplace hazards.
4. Impacts on Medical Device and Drug Approvals
The FDA has also experienced deep cuts, including leadership positions in critical areas like food safety and drug evaluation. While HHS claims that the restructuring will not directly affect FDA reviewers and inspectors, the shake-up in leadership and administrative operations could potentially lead to delays in the approval of new drugs and medical devices. Vaccine recommendations and regulatory processes may also face challenges due to the layoffs and restructuring at the FDA.
5. Concerns about Transparency and Accountability
The lack of transparency regarding the personnel cuts at HHS raises concerns about accountability and public access to information. The reduction in communications and media offices, including those handling Freedom of Information Act requests, could limit public access to government data and documents. This move threatens transparency and accountability in government operations, leaving taxpayers and stakeholders with limited information about the impacts of the staffing reductions.
Demanding Accountability
As the repercussions of the personnel cuts at HHS continue to unfold, it is crucial for concerned individuals to demand transparency and accountability from the agency. Contacting Congresspeople and advocating for access to information about the effects of the staff reductions on public health and safety can help ensure that critical public health initiatives and biomedical research efforts are not compromised.
Natalie Gehred is a PhD Candidate in Molecular Biology at UCLA and a Science Policy Intern at the Union of Concerned Scientists. Natalie’s research focuses on cardiac scarring in heart failure, and she is passionate about evidence-based healthcare and health policy.
